Does the media favor OCUL or CRNX?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Ocular Therapeutix and 4 mentions for Crinetics Pharmaceuticals. Ocular Therapeutix's average media sentiment score of 1.55 beat Crinetics Pharmaceuticals' score of 1.17 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLTE or OCUL?

In the previous week, Belite Bio had 14 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for Belite Bio and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Belite Bio's score of 0.39 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, OCUL or LNTH?

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocular Therapeutix $51.95M 44.35 -$265.94M -$1.42 N/A Lantheus $1.54B 4.24 $233.56M $4.14 24.21

Does the media favor OCUL or LNTH?

In the previous week, Lantheus had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 7 mentions for Lantheus and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Lantheus' score of 0.81 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LQDA or OCUL?

Liquidia has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 37.73 -$68.92M $1.37 48.72 Ocular Therapeutix $51.95M 44.35 -$265.94M -$1.42 N/A

Does the media prefer LQDA or OCUL?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for Ocular Therapeutix and 4 mentions for Liquidia. Ocular Therapeutix's average media sentiment score of 1.55 beat Liquidia's score of 1.04 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to AMRX or OCUL?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Amneal Pharmaceuticals' score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Ocular Therapeutix (OCUL) Competitors

$10.49 -0.13 (-1.22%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$10.69 +0.20 (+1.90%)

As of 09/11/2026 07:56 PM Eastern

Compare

OCUL vs. CRNX, BLTE, LNTH, LQDA, and AMRX

Should you buy Ocular Therapeutix stock or one of its competitors? Ocular Therapeutix's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ocular Therapeutix compare to Crinetics Pharmaceuticals?

Ocular Therapeutix (NASDAQ:OCUL) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ocular Therapeutix has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	44.35	-$265.94M	-$1.42	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Ocular Therapeutix presently has a consensus price target of $25.75, indicating a potential upside of 145.47%. Crinetics Pharmaceuticals has a consensus price target of $81.00, indicating a potential downside of 4.65%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Ocular Therapeutix has a net margin of -579.10% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Ocular Therapeutix had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Ocular Therapeutix and 4 mentions for Crinetics Pharmaceuticals. Ocular Therapeutix's average media sentiment score of 1.55 beat Crinetics Pharmaceuticals' score of 1.17 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Summary

Ocular Therapeutix beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Belite Bio has higher earnings, but lower revenue than Ocular Therapeutix. Belite Bio is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Ocular Therapeutix	$51.95M	44.35	-$265.94M	-$1.42	N/A

Belite Bio presently has a consensus price target of $218.73, indicating a potential upside of 25.86%. Ocular Therapeutix has a consensus price target of $25.75, indicating a potential upside of 145.47%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Belite Bio has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Belite Bio's return on equity of -11.84% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

In the previous week, Belite Bio had 14 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for Belite Bio and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Belite Bio's score of 0.39 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

Ocular Therapeutix beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Lantheus?

Ocular Therapeutix (NASDAQ:OCUL) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	44.35	-$265.94M	-$1.42	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Ocular Therapeutix's net margin of -579.10%. Lantheus' return on equity of 28.10% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Lantheus	17.69%	28.10%	14.35%

Ocular Therapeutix currently has a consensus price target of $25.75, indicating a potential upside of 145.47%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.84%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 7 mentions for Lantheus and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Lantheus' score of 0.81 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

Summary

Lantheus beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 46.96%. Ocular Therapeutix has a consensus price target of $25.75, indicating a potential upside of 145.47%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Liquidia has a net margin of 30.74% compared to Ocular Therapeutix's net margin of -579.10%. Liquidia's return on equity of 149.65% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

In the previous week, Ocular Therapeutix had 1 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for Ocular Therapeutix and 4 mentions for Liquidia. Ocular Therapeutix's average media sentiment score of 1.55 beat Liquidia's score of 1.04 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Liquidia has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.73	-$68.92M	$1.37	48.72
Ocular Therapeutix	$51.95M	44.35	-$265.94M	-$1.42	N/A

Summary

Liquidia beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Amneal Pharmaceuticals presently has a consensus price target of $19.57, suggesting a potential upside of 15.06%. Ocular Therapeutix has a consensus price target of $25.75, suggesting a potential upside of 145.47%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Amneal Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.80	$72.06M	$0.49	34.71
Ocular Therapeutix	$51.95M	44.35	-$265.94M	-$1.42	N/A

Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Ocular Therapeutix's net margin of -579.10%. Ocular Therapeutix's return on equity of -59.89% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 5 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.55 beat Amneal Pharmaceuticals' score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Amneal Pharmaceuticals beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.33B	$12.46B	$7.14B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-7.39	799.75	275.24	25.29
Price / Sales	44.35	763.36	656.02	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	3.42	10.39	10.33	6.20
Net Income	-$265.94M	$2.85B	$3.50B	$358.50M
7 Day Performance	-1.41%	-3.61%	-3.32%	-2.35%
1 Month Performance	2.54%	0.86%	-0.41%	-2.77%
1 Year Performance	-18.11%	3.47%	19.21%	7.63%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	3.7227 of 5 stars	$10.49 -1.2%	$25.75 +145.5%	-17.9%	$2.33B	$51.95M	N/A	325	Positive News
CRNX Crinetics Pharmaceuticals	1.4876 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	Positive News
BLTE Belite Bio	3.7451 of 5 stars	$193.61 flat	$214.64 +10.9%	+153.5%	$7.80B	N/A	N/A	10	Analyst Forecast Insider Trade Gap Up High Trading Volume
LNTH Lantheus	3.6328 of 5 stars	$100.97 flat	$108.11 +7.1%	+82.3%	$6.59B	$1.54B	24.39	1,193	News Coverage Positive News Analyst Downgrade
LQDA Liquidia	3.8001 of 5 stars	$68.66 flat	$98.08 +42.9%	+147.2%	$6.15B	$158.32M	50.12	50	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does Ocular Therapeutix compare to Crinetics Pharmaceuticals?

Summary

How does Ocular Therapeutix compare to Belite Bio?

Summary

How does Ocular Therapeutix compare to Lantheus?

Summary

How does Ocular Therapeutix compare to Liquidia?

Summary

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does Ocular Therapeutix compare to Crinetics Pharmaceuticals?

Do insiders & institutionals have more ownership in OCUL or CRNX?

Which has preferable earnings and valuation, OCUL or CRNX?

Do analysts rate OCUL or CRNX?

Is OCUL or CRNX more profitable?

Does the media favor OCUL or CRNX?

Which has more risk & volatility, OCUL or CRNX?

Summary

How does Ocular Therapeutix compare to Belite Bio?

Do insiders & institutionals believe in BLTE or OCUL?

Which has better valuation and earnings, BLTE or OCUL?

Do analysts prefer BLTE or OCUL?

Is BLTE or OCUL more profitable?

Does the media refer more to BLTE or OCUL?

Which has more risk and volatility, BLTE or OCUL?

Summary

How does Ocular Therapeutix compare to Lantheus?

Which has better earnings and valuation, OCUL or LNTH?

Do institutionals & insiders believe in OCUL or LNTH?

Is OCUL or LNTH more profitable?

Do analysts prefer OCUL or LNTH?

Does the media favor OCUL or LNTH?

Which has more volatility & risk, OCUL or LNTH?

Summary

How does Ocular Therapeutix compare to Liquidia?

Do analysts prefer LQDA or OCUL?

Do institutionals & insiders believe in LQDA or OCUL?

Is LQDA or OCUL more profitable?

Does the media prefer LQDA or OCUL?

Which has more volatility & risk, LQDA or OCUL?

Which has preferable valuation & earnings, LQDA or OCUL?

Summary

How does Ocular Therapeutix compare to Amneal Pharmaceuticals?

Do analysts recommend AMRX or OCUL?

Which has stronger valuation & earnings, AMRX or OCUL?

Which has more risk and volatility, AMRX or OCUL?

Do institutionals & insiders hold more shares of AMRX or OCUL?

Is AMRX or OCUL more profitable?

Does the media refer more to AMRX or OCUL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools